Royalty Pharma (RPRX) Short Interest Ratio & Short Volume $35.88 -0.15 (-0.42%) Closing price 04:00 PM EasternExtended Trading$35.94 +0.05 (+0.15%) As of 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Royalty Pharma Short Interest DataRoyalty Pharma (RPRX) has a short interest of 29.03 million shares, representing 8.74% of the float (the number of shares available for trading by the public). This marks a 0.03% increase in short interest from the previous month. The short interest ratio (days to cover) is 5.6, indicating that it would take 5.6 days of the average trading volume of 3.68 million shares to cover all short positions.Current Short Interest29,030,000 sharesPrevious Short Interest29,020,000 sharesChange Vs. Previous Month+0.03%Dollar Volume Sold Short$1.01 billionShort Interest Ratio5.6 Days to CoverLast Record DateJune 15, 2025Outstanding Shares562,240,000 sharesFloat Size332,240,000 sharesShort Percent of Float8.74%Today's Trading Volume4,697,537 sharesAverage Trading Volume3,680,148 sharesToday's Volume Vs. Average128% Short Selling Royalty Pharma? Sign up to receive the latest short interest report for Royalty Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartRPRX Short Interest Over TimeRPRX Days to Cover Over TimeRPRX Percentage of Float Shorted Over Time Royalty Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/15/202529,030,000 shares $1.01 billion +0.0%8.7%5.6 $34.84 5/31/202529,020,000 shares $959.40 million +39.9%8.7%5.9 $33.06 5/15/202520,740,000 shares $686.91 million +11.6%6.2%4.3 $33.12 4/30/202518,590,000 shares $610.12 million -9.6%5.4%4 $32.82 4/15/202520,570,000 shares $667.50 million +14.2%6.2%4.5 $32.45 3/31/202518,010,000 shares $560.65 million +15.7%5.4%3.8 $31.13 3/15/202515,570,000 shares $510.23 million +13.2%4.7%3.7 $32.77 2/28/202513,750,000 shares $462.55 million -10.1%4.1%3.3 $33.64 2/15/202515,300,000 shares $495.11 million -5.2%4.1%3.9 $32.36 1/31/202516,130,000 shares $509.39 million -3.0%4.2%4.3 $31.58 Get the Latest News and Ratings for RPRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Royalty Pharma and its competitors with MarketBeat's FREE daily newsletter. 1/15/202516,630,000 shares $511.21 million +0.4%4.4%5 $30.74 12/31/202416,560,000 shares $422.45 million +5.8%4.4%5.8 $25.51 12/15/202415,650,000 shares $388.75 million -0.3%4.1%5.8 $24.84 11/30/202415,700,000 shares $418.56 million +7.0%4.1%6.4 $26.66 11/15/202414,670,000 shares $377.02 million +0.8%3.9%6.1 $25.70 10/31/202414,550,000 shares $392.85 million +0.6%3.8%6.5 $27.00 10/15/202414,460,000 shares $402.57 million -0.8%3.8%6 $27.84 9/30/202414,570,000 shares $412.19 million +2.7%3.8%5.9 $28.29 9/15/202414,190,000 shares $393.35 million -3.3%3.7%5.4 $27.72 8/31/202414,680,000 shares $426.16 million +2.8%3.8%5.5 $29.03 8/15/202414,280,000 shares $391.41 million -4.0%3.7%5 $27.41 7/31/202414,870,000 shares $418.89 million -9.8%3.9%5.4 $28.17 7/15/202416,490,000 shares $439.46 million -2.4%4.3%6.1 $26.65 6/30/202416,900,000 shares $445.65 million +8.8%4.4%6.1 $26.37 6/15/202415,540,000 shares $418.34 million +17.3%4.1%5.8 $26.92 5/31/202413,250,000 shares $363.18 million -0.2%3.5%4.9 $27.41 5/15/202413,280,000 shares $374.63 million -3.4%3.5%5.1 $28.21 4/30/202413,750,000 shares $380.88 million -2.8%3.6%4.8 $27.70 4/15/202414,150,000 shares $399.74 million +14.2%3.7%5.2 $28.25 3/31/202412,390,000 shares $376.28 million -2.1%3.3%4.7 $30.37 3/15/202412,650,000 shares $380.64 million -3.7%3.3%4.9 $30.09 2/29/202413,130,000 shares $398.36 million +14.2%3.5%4.8 $30.34 2/15/202411,500,000 shares $345.35 million +11.9%3.0%4.1 $30.03 1/31/202410,280,000 shares $291.85 million +0.9%2.7%4.1 $28.39 1/15/202410,190,000 shares $289.19 million -9.1%2.7%4.3 $28.38 12/31/202311,210,000 shares $314.89 million -9.2%2.9%4.8 $28.09 12/15/202312,340,000 shares $337.75 million +23.3%3.2%5.3 $27.37 11/30/202310,010,000 shares $270.97 million +1.8%2.6%4.3 $27.07 11/15/20239,830,000 shares $265.61 million -10.4%2.6%4.5 $27.02 10/31/202310,970,000 shares $294.76 million -2.8%2.9%5 $26.87A grave, grave error. (Ad)President Donald Trump made headlines last month with a staggering claim. He stated that since taking office, more than $12 trillion in private investments into America have been “practically committed” on his watch. "Nobody's ever seen numbers like we have," he said, crediting his agenda of tariffs, tax cuts, and deregulation with making the difference. If true, the figure would indeed be astonishing – potentially tripling the roughly $4 trillion in gross private investment the US reported all of last year.That means that you could still get in early on the biggest technological shift in history. But onl 10/15/202311,290,000 shares $314.31 million +8.0%3.0%5.2 $27.84 9/30/202310,450,000 shares $283.61 million +11.7%2.8%4.8 $27.14 9/15/20239,360,000 shares $263.30 million +9.5%2.5%4.3 $28.13 8/31/20238,550,000 shares $254.96 million -8.7%2.3%3.7 $29.82 8/15/20239,360,000 shares $278.93 million +0.2%2.5%3.9 $29.80 7/31/20239,340,000 shares $293.09 million -14.2%2.5%3.9 $31.38 7/15/202310,890,000 shares $334.65 million +23.2%2.9%4.6 $30.73 6/30/20238,840,000 shares $271.74 million +1.1%2.4%3.9 $30.74 6/15/20238,740,000 shares $281.43 million +15.3%2.3%4 $32.20 5/31/20237,580,000 shares $248.17 million +5.6%2.0%3.7 $32.74 5/15/20237,180,000 shares $246.49 million -7.4%1.9%3.7 $34.33 4/30/20237,750,000 shares $272.41 million +1.7%2.1%4.1 $35.15 4/15/20237,620,000 shares $276.30 million +0.9%2.1%4.1 $36.26 3/31/20237,550,000 shares $272.03 million -1.2%2.0%4 $36.03 3/15/20237,640,000 shares $263.58 million +3.7%2.1%4.2 $34.50 2/28/20237,370,000 shares $264.21 million +7.1%2.0%4.5 $35.85 2/15/20236,880,000 shares $259.31 million +8.2%1.9%4.4 $37.69 1/31/20236,360,000 shares $249.25 million -10.4%1.7%4.2 $39.19 1/15/20237,100,000 shares $279.53 million -9.0%1.9%4.8 $39.37 12/30/20227,800,000 shares $308.26 million +4.4%2.1%5.3 $39.52 12/15/20227,470,000 shares $304.70 million -2.9%2.0%4.9 $40.79 11/30/20227,690,000 shares $338.13 million +35.6%2.1%4.7 $43.97 11/15/20225,670,000 shares $238.59 million -14.7%1.6%3.4 $42.08 10/31/20226,650,000 shares $281.43 million -22.1%1.8%4.1 $42.32 10/15/20228,540,000 shares $353.64 million -0.5%2.4%5 $41.41 9/30/20228,580,000 shares $344.74 million -5.3%2.4%4.6 $40.18 9/15/20229,060,000 shares $382.06 million -9.9%2.5%4.6 $42.17 8/31/202210,050,000 shares $420.19 million -17.3%2.8%5.2 $41.81 8/15/202212,150,000 shares $533.75 million -10.0%3.3%6.2 $43.93 7/31/202213,500,000 shares $587.12 million +0.5%3.7%6.4 $43.49 7/15/202213,430,000 shares $589.98 million +0.8%3.7%6.2 $43.93 6/30/202213,330,000 shares $560.39 million -2.9%3.7%5.7 $42.04 6/15/202213,730,000 shares $529.02 million +35.9%3.8%5.7 $38.53 5/31/202210,100,000 shares $415.51 million +21.0%2.8%4.7 $41.14 5/15/20228,350,000 shares $333.50 million +13.5%2.3%4 $39.94 4/30/20227,360,000 shares $313.39 million -10.1%2.0%3.8 $42.58 4/15/20228,190,000 shares $361.18 million +17.5%2.3%4.4 $44.10 3/31/20226,970,000 shares $271.55 million +11.3%1.9%4.1 $38.96 3/15/20226,260,000 shares $239.57 million +4.5%1.7%4.1 $38.27 2/28/20225,990,000 shares $235.17 million +7.2%1.7%3.7 $39.26 2/15/20225,590,000 shares $225.50 million -7.3%1.6%3 $40.34 1/31/20226,030,000 shares $241.26 million -4.3%1.7%2.9 $40.01 1/15/20226,300,000 shares $249.86 million +7.7%1.8%2.9 $39.66 12/31/20215,850,000 shares $233.12 million -17.7%1.6%2.8 $39.85 12/15/20217,110,000 shares $266.77 million +20.3%2.0%3.5 $37.52 11/30/20215,910,000 shares $235.04 million -10.1%1.7%2.4 $39.77 11/15/20216,570,000 shares $273.97 million -17.6%1.9%2.8 $41.70 10/29/20217,970,000 shares $315.05 million +2.1%2.4%3.7 $39.53 10/15/20217,810,000 shares $299.83 million -7.4%2.3%3.3 $38.39 9/30/20218,430,000 shares $304.66 million +40.3%2.5%3.5 $36.14A grave, grave error. (Ad)President Donald Trump made headlines last month with a staggering claim. He stated that since taking office, more than $12 trillion in private investments into America have been “practically committed” on his watch. "Nobody's ever seen numbers like we have," he said, crediting his agenda of tariffs, tax cuts, and deregulation with making the difference. If true, the figure would indeed be astonishing – potentially tripling the roughly $4 trillion in gross private investment the US reported all of last year.That means that you could still get in early on the biggest technological shift in history. But onl 9/15/20216,010,000 shares $228.20 million +2.2%1.8%2.4 $37.97 8/31/20215,880,000 shares $227.26 million -22.5%1.8%2.7 $38.65 8/13/20217,590,000 shares $293.96 million -15.6%2.3%3.3 $38.73 7/30/20218,990,000 shares $343.42 million -11.5%3.0%4 $38.20 7/15/202110,160,000 shares $407.21 million +8.6%3.4%5.3 $40.08 6/30/20219,360,000 shares $383.67 million -30.3%3.1%4.9 $40.99 6/15/202113,420,000 shares $590.75 million -15.7%4.5%7.6 $44.02 5/28/202115,910,000 shares $638.31 million -12.4%5.3%6.5 $40.12 5/14/202118,170,000 shares $730.07 million +10.6%6.1%7.2 $40.18 4/30/202116,430,000 shares $727.85 million -8.1%5.4%6.3 $44.30 4/15/202117,880,000 shares $753.11 million -1.4%5.9%6.7 $42.12 3/31/202118,140,000 shares $791.45 million +30.1%6.0%6 $43.63 3/15/202113,940,000 shares $654.06 million +31.0%4.6%3.9 $46.92 2/26/202110,640,000 shares $500.29 million +31.5%3.5%3.7 $47.02 2/12/20218,090,000 shares $382.74 million -7.1%2.6%3 $47.31 1/29/20218,710,000 shares $423.83 million -3.3%2.8%3.3 $48.66 1/15/20219,010,000 shares $461.76 million No Change2.9%3.4 $51.25 RPRX Short Interest - Frequently Asked Questions What is Royalty Pharma's current short interest? Short interest is the volume of Royalty Pharma shares that have been sold short but have not yet been closed out or covered. As of June 15th, traders have sold 29,030,000 shares of RPRX short. 8.74% of Royalty Pharma's shares are currently sold short. Learn More on Royalty Pharma's current short interest. What is a good short interest ratio for Royalty Pharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. RPRX shares currently have a short interest ratio of 6.0. Learn More on Royalty Pharma's short interest ratio. Which institutional investors are shorting Royalty Pharma? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Royalty Pharma: Jane Street Group LLC, Millennium Management LLC, Caption Management LLC, Twin Tree Management LP, and Jane Street Group LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Royalty Pharma? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 8.74% of Royalty Pharma's floating shares are currently sold short. Is Royalty Pharma's short interest increasing or decreasing? Royalty Pharma saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 29,030,000 shares, an increase of 0.0% from the previous total of 29,020,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Royalty Pharma's float size? Royalty Pharma currently has issued a total of 562,240,000 shares. Some of Royalty Pharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Royalty Pharma currently has a public float of 332,240,000 shares. How does Royalty Pharma's short interest compare to its competitors? 8.74% of Royalty Pharma's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Royalty Pharma: Zoetis Inc. (1.95%), Corcept Therapeutics Incorporated (13.49%), Jazz Pharmaceuticals PLC (10.11%), Perrigo Company plc (3.63%), Supernus Pharmaceuticals, Inc. (7.61%), Pacira BioSciences, Inc. (12.92%), Omeros Corporation (23.40%), Assembly Biosciences, Inc. (0.41%), Nektar Therapeutics (4.98%), Cumberland Pharmaceuticals Inc. (0.82%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($69.26 billion), Invesco QQQ ($25.22 billion), iShares Russell 2000 ETF ($20.33 billion), iShares 20+ Year Treasury Bond ETF ($9.99 billion), MicroStrategy Incorporated ($9.12 billion), Canadian Natural Resources Limited ($6.73 billion), SPDR S&P Biotech ETF ($6.52 billion), Invesco S&P 500 Equal Weight ETF ($5.60 billion), Financial Select Sector SPDR Fund ($4.64 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.59 billion). View all of the most shorted stocks. What does it mean to sell short Royalty Pharma stock? Short selling RPRX is an investing strategy that aims to generate trading profit from Royalty Pharma as its price is falling. RPRX shares are trading down $0.15 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Royalty Pharma? A short squeeze for Royalty Pharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of RPRX, which in turn drives the price of the stock up even further. How often is Royalty Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RPRX, twice per month. The most recent reporting period available is June, 15 2025. More Short Interest Resources from MarketBeat Related Companies ZTS Short Interest CORT Short Interest JAZZ Short Interest PRGO Short Interest SUPN Short Interest PCRX Short Interest OMER Short Interest ASMB Short Interest NKTR Short Interest CPIX Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:RPRX) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold Shock (insane new prediction)World Gold Council reports: "No sign" of this catalyst slowing A whopping 73% of Americans report they're "...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Royalty Pharma PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Royalty Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
